Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory Disease and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SLPI drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SLPI Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native folding. |
View SLPI Products |
| Gene Delivery | SLPI Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression assays. |
View SLPI Products |
| Benchmark Ab | Anti-SLPI Recombinant Antibody Recombinant positive control antibody for binding and functional assays. |
View SLPI Products |
| Validator | SLPI siRNA Set Target-specific knockdown verification in phenotypic assays. |
View SLPI Products |
| Related Target A | ELANE (Neutrophil Elastase) Primary physiological target inhibited by SLPI; crucial for protease-antiprotease balance assays. |
View ELANE Products |
| Related Target B | PI3 (Elafin) Complementary low-molecular-weight serine protease inhibitor sharing similar mucosal protective roles. |
View PI3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Active site conformation preservation | HEK293 mammalian expression system guarantees correct disulfide bond formation and native glycosylation. |
| Protease-antiprotease assay interference | Ultra-low endotoxin control (<1.0 EU/μg) prevents non-specific immune activation in cell-based assays. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) and sequence-verified positive controls included. |
| False Positives | Validated siRNA set included for target-specific knockdown and validation. |
Live SLPI R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SLPI therapeutics is intensifying, with major players shifting focus from traditional mAbs to recombinant protein replacement therapies and targeted inhibitors. As first-generation therapies reach the clinic, the next wave of R&D is targeting SLPI's dual role: as an anti-inflammatory agent in pulmonary diseases (such as COPD and cystic fibrosis) and as an oncogenic promoter in aggressive solid tumors where it facilitates metastasis and immune evasion.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Recombinant Protein | AstraZeneca, Academic Institutions | COPD, Cystic Fibrosis, ARDS | Elastase Inhibition Assay (Need highly active, native-folded SLPI protein) |
| Monoclonal Antibody | Oncology-focused Biotechs | Ovarian Cancer, Triple-Negative Breast Cancer | Epitope Mapping & Blockade Verification (Need sequence-verified antigens) |
| Gene Therapy / mRNA | Pulmonary Delivery Specialists | Alpha-1 Antitrypsin Deficiency, Lung Injury | In vitro Expression Validation (Need high-titer Lentivirus and qPCR controls) |